- Details
- Alicia Morgans interviews Andre Esteva about ArteraAI's expanded prostate cancer test, now validated for low-risk and active surveillance patients. Dr. Esteva explains that the AI-driven test helps clinicians decide between active surveillance and definitive treatment by assessing the risk of adverse pathology at prostatectomy. The test, which uses digital pathology to analyze H&E slides without c...
|
- Details
- Seth Lerner discusses the SWOG study on standard versus extended lymphadenectomy for muscle-invasive bladder cancer published October 2024 in the New England Journal of Medicine. Dr. Lerner describes the trial's background, design, and key findings. The study, involving 592 patients with a median follow-up of 6.1 years, shows no benefit in disease-free or overall survival with extended lymphadenec...
|
- Details
- Phillip Koo and Zachary Klaassen discuss the UpFrontPSMA study, a Phase 2 trial published in Lancet Oncology. The study evaluates lutetium-177 PSMA-617 followed by docetaxel versus docetaxel alone in patients with de novo high-volume metastatic hormone-sensitive prostate cancer. They highlight the trial design, which uses PSMA and FDG PET for patient selection, and discuss key results. The primary...
|
- Details
- Zachary Klaassen hosts Sarah Howlett and Mahaz Kayani about the STAMPEDE2 platform trial, focusing on Arm N, which tests niraparib-abiraterone in metastatic hormone-sensitive prostate cancer patients with specific homologous recombination repair gene alterations. They discuss the trial's design, which randomizes patients to receive either a dual-action tablet of niraparib-abiraterone or standard A...
|
- Details
- Bram De Laere discusses the ProBio trial, a platform study for metastatic prostate cancer. Dr. De Laere explains the trial's unique design, which uses circulating tumor DNA analysis to guide treatment decisions and evaluate multiple biomarker-therapy combinations simultaneously. The study demonstrates that AR pathway inhibitors generally outperform taxane-based chemotherapy in mCRPC patients, with...
|
- Details
- Asunción Hervás disccusses the HYPORT-ES trial, which examines hypofractionated postoperative radiotherapy in prostate cancer. Dr. Hervás discusses the phase II trial's design, which evaluated the efficacy and toxicity of moderate hypofractionation (62.5 Gy in 25 fractions) for adjuvant and salvage radiotherapy. The study, involving 405 patients from 23 Spanish centers, shows low rates of acute an...
|
- Details
- Ruchika Talwar interviews Brian Lane about a MUSIC collaborative study on same-day discharges for radical prostatectomy patients in Michigan. Dr. Lane discusses the study's findings, which show that only 2.8% of patients had same-day discharges between 2018 and 2022, despite efforts to increase uptake. The study demonstrates that same-day discharge is safe, with readmission rates comparable to one...
|
- Details
- Zachary Klaassen interviews Alison Tree about the PACE-C trial, comparing moderate hypofractionation to stereotactic body radiotherapy (SBRT) in unfavorable and high-risk prostate cancer patients. Dr. Tree discusses the trial design, which randomized 1,208 men to receive either standard 60 Gy in 20 fractions over four weeks or SBRT with 36.25-40 Gy in five fractions. The acute toxicity results sho...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the ARANOTE trial, a phase III study evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer. They highlight the trial's design, which randomized 669 patients to darolutamide plus ADT or placebo plus ADT. The study meets its primary endpoint, showing significant improvement in radiographic progression-free survival for the darolutami...
|
- Details
- Thomas Powles discusses the EV-302 trial data, (Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer) focusing on biomarker analyses for enfortumab vedotin (EV) plus pembrolizumab in urothelial cancer. Dr. Powles discusses the lack of discriminatory effect for PD-L1 and nectin-4 expression as biomarkers, noting that nectin-4 is nearly universally expressed in urothelial can...
|
